Global Blood Therapeutics Profit Margin

The latest profit margin for GBT is -138.97% as of June 2022. That compares with -161.55% in the prior-year period — up 14.0% year over year. That is below the Healthcare sector average of 15.29%. Investors often review this figure alongside Global Blood Therapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, GBT's profit margin moved from -161.55% to -138.97% — a 14.0% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Global Blood Therapeutics's valuation or profitability profile.

Against Healthcare companies, GBT currently prints -138.97% for profit margin, while the sector average sits near 15.29%. That is roughly 1008.7% below the sector mean. Large gaps often invite a closer look at Global Blood Therapeutics's growth, margins, and balance sheet.

Profit Margin shows how effectively Global Blood Therapeutics converts resources into returns. At -138.97%, GBT may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -161.55% in the prior-year period — up 14.0% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting GBT's profit margin (-138.97%), review year-over-year change from -161.55%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.